title: Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future.
authors.affiliation: Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: roberto.iacovelli@ospedaleuniverona.it.
authors.forename: Roberto
authors.initials: R
authors.lastname: Iacovelli
authors.affiliation: Urology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
authors.forename: Walter
authors.initials: W
authors.lastname: Artibani
authors.affiliation: Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Tortora
mesh_terms: D002292:Carcinoma, Renal Cell; D006801:Humans; D007680:Kidney Neoplasms; D058990:Molecular Targeted Therapy; D016609:Neoplasms, Second Primary; D011379:Prognosis